Premium
Arginine—Dual roles as an onconutrient and immunonutrient
Author(s) -
Albaugh Vance L.,
PinzonGuzman Carolina,
Barbul Adrian
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24490
Subject(s) - arginine , medicine , malignancy , cancer , immune system , cancer therapy , limiting , adjuvant , adjuvant therapy , cancer research , oncology , immunology , biochemistry , amino acid , biology , mechanical engineering , engineering
Arginine is an important player in numerous biologic processes and studies have demonstrated its importance for cellular growth that becomes limiting in states of rapid turnover (e.g., malignancy). Thus, arginine deprivation therapy is being examined as an adjuvant cancer therapy, however, arginine is also necessary for immune destruction of malignant cells. Herein we review the data supporting arginine deprivation or supplementation in cancer treatment and the currently registered trials aimed at understanding these divergent strategies. J. Surg. Oncol. 2017;115:273–280 . © 2016 Wiley Periodicals, Inc.